spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Recipharm and Laccure agree commercial collaboration

Recipharm Pharmaceutical Development AB

Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary

The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products.

Over the past years, Laccure AB has successfully taken the product from innovation through clinical studies to commercial manufacturing. The development work was focused on creating a highly effective antibiotic-free product that was also user-friendly in terms of being easy to apply and not messy to use. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure® Pessary and the exact date for the launch will be announced next year.

Laccure AB is a project company within the life science development organisation Partners for Development Investments in Life Sciences (P.U.L.S.). As it prepares for launch, the owner is endeavouring to sell the company to a buyer with the substantial resources required to bring the product to market.

Jeanette Robertsson, CEO of Laccure AB, said: “We are delighted to be collaborating with Recipharm, they are an expert partner that we can rely on for the commercial supply of our new product.

“Given the potential market for the product, a major benefit of partnering with Recipharm is that they have a high level of production capacity, which of course gives us the possibility to further scale up the batch size to meet market requirements in the future.”

It is estimated that more than 300 million women throughout the world suffer from bacterial vaginosis every year, however, there are currently no effective and safe products available that are also user-friendly and can be used with low-frequency dosages.

Laccure® Pessary is based on a patented substance that releases lactic acid, and only needs to be administered once to treat a bacterial vaginosis infection and then once a month to prevent a recurrence.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: “We are really looking forward to the commercial launch of this product, and contributing to something that will make a major difference to the lives of many women across the globe.”
web www.recipharm.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Denny Bros Group continues its support of Packaging Innovations

A world leading print company is preparing to showcase its renowned labelling and printing solutions at next month’s prestigious Packaging Innovations show.
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement